Features of Polypharmacy in Dutch Older Outpatients with Personality Disorders: A Cross-sectional Study
Julie E. M. SCHULKENSContact / Kontakt / Kapcsolat, Sebastiaan (Bas) P. J. VAN ALPHEN, Frans R. J. VERHEY & Sjacko SOBCZAK
EJMH Vol 19, e0016 (2024) 1-10; https://doi.org/10.5708/EJMH.19.2024.0016
Received: 15 January 2023; Accepted: 22 January 2024; Online: 26 February 2024
Section: Research Papers
Download full text

Abstract

Introduction: Pharmacotherapy in older adults with personality disorders (PDs) can be even more complicated compared to younger adults, because older adults stand at risk for polypharmacy and its negative consequences due to somatic comorbidities and biological age-related changes.

Aims: This study’s primary objective serves to describe the point prevalence of polypharmacy in older adults with PDs. Next, we described 1) the number of psychotropics employed, 2) classes of psychotropics, 3) the number of somatic medication, and 4) the anticholinergic burden of the total medication.

Methods: This cross sectional study was performed at a clinical center of excellence for older adults with PDs in the Netherlands. Fifty outpatients aged 65 years and older with a primary diagnosis of a PD were selected from an alphabetically ordered list. Data from the files on polypharmacy (use of five medications or more daily), use of medication and the anticholinergic burden (ARS score) was collected.

Results: Polypharmacy was present in 72% of older adults with PDs. The mean number of psychotropics was 2.0 (SD 1.4) psychotropics per person, for somatic medication the mean was 6.2 (SD 3.6). Antidepressants were the most frequently prescribed (used by 62%), followed by anxiolytics (used by 40%). The mean ARS score was 1.1 points (SD 1.7).

Conclusions: The prevalence of polypharmacy in older adults with PDs stands high, due to the high use of both psychotropics and somatic medication. Although this study provides important and new information on the use of medication in older adults, its representation of the population may be limited due to the tertiary care setting and small sample size excluding certain PDs (e.g., schizoid or obsessive-compulsive PD). Also, we did not register or measure the consequences of polypharmacy.

Keywords

polypharmacy, pharmacotherapy, anticholinergic burden, personality disorders, geriatric psychiatry

Corresponding author

Julie E. M. SCHULKENS

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health and Life Sciences (FHML), Maastricht University, The Netherlands 
Mondriaan Mental Health Center, Center of Excellence for Personality Disorders in Older Adults, Heerlen-Maastricht, The Netherlands

julie.schulkens@maastrichtuniversity.nl

https://orcid.org/0000-0002-0279-4137

Co-authors

Sebastiaan (Bas) P. J. VAN ALPHEN
Mondriaan Mental Health Center, Center of Excellence for Personality Disorders in Older Adults, Heerlen-Maastricht, The Netherlands
Department of Psychology, Faculty of Psychology & Educational Sciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium
Department of Medical and Clinical Psychology, School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands
https://orcid.org/0000-0001-7085-3349

Frans R. J. VERHEY
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health and Life Sciences (FHML), Maastricht University, The Netherlands
https://orcid.org/0000-0002-8307-8406

Sjacko SOBCZAK
Mondriaan Mental Health Center, Center of Excellence for Personality Disorders in Older Adults, Heerlen-Maastricht, The Netherlands Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, The Netherlands
https://orcid.org/0000-0001-6351-0479

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.